alercet 10 mg cápsulas blandas
procaps s.a. - cápsula blanda - 10 mg
alercet 10 mg/ml. solución oral
procaps s.a. - solución oral - 10 mg/ml
alercet®
laboratorios siegfried s.a. [ec] ecuador - cetirizina clorhidrato 1 mg/ml - jarabe - cada 100 ml de jarabe contienen: cetirizina clorhidrato 100.00 mg
alercet df capsulas
laboratorios siegfried s.a. [ec] ecuador - 78.500 mg 75.000 mg - cÁpsula - cada cápsula contiene: cetirizina diclorhidrato microgránulos????????? 78.5000 mg (6.37%) (equivalente a 5mg de cetirizina diclorhidrato) fenilefrina clorhidrato microgránulos ??????????75.0000 mg (20%) (equivalente a 15 mg de fenilefrina clorhidrato) composiciÓn de cetirizina microgrÁnulos cetirizina diclorhidrato 5.0000 mg croscarmelosa sódica 0.2579 mg talco blanco 6.2469 mg almidón 41.8590 mg sacarosa 22.5399 mg povidona 2.5963 mg composiciÓn de fenilefrina microgrÁnulos fenilefrina clorhidrato 15.000 mg cristales de azúcar 41.6475 mg etil celulosa 3.2850 mg talco 13.2675 mg laca 1.8000 mg alcohol etílico* *se evapora durante el proceso
alercet df jarabe
laboratorios siegfried s.a. [ec] ecuador - cetirizina diclorhidrato ????100.00 mg fenilefrina clorhidrato?????200.000 mg - jarabe - cada 100 ml de jarabe contienen: cetirizina diclorhidrato ??????100.00 mg (exceso 5.00 mg: 5%) fenilefrina clorhidrato???????200.00 mg (exceso 10.00 mg: 5%)
jayempi
nova laboratories ireland limited - azathioprine - rechazo del injerto - inmunosupresores - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.
otezla
amgen europe bv - apremilast - arthritis, psoriatic; psoriasis - inmunosupresores - psoriásica arthritisotezla, solo o en combinación con fármacos antirreumáticos modificadores de la enfermedad (dmard), está indicado para el tratamiento de los activos de la artritis psoriásica (psa) en pacientes adultos que han tenido una respuesta inadecuada o que han sido intolerantes a una anterior, una terapia con dmard. psoriasisotezla está indicado para el tratamiento de moderada a severa psoriasis en placas crónica en pacientes adultos que no han respondido o que tienen una contraindicación de, o intolerancia a la otra terapia sistémica incluyendo ciclosporina, metotrexato o psoraleno y luz ultravioleta la luz (puva).
genvinset hla behcet v5.
maskaf s.a.c. -
ciqorin 25 mg capsulas blandas efg
teva pharma s.l.u. - ciclosporina - cÁpsula blanda - 25 mg - ciclosporina 25 mg - ciclosporina
ciqorin 50 mg capsulas blandas efg
teva pharma s.l.u. - ciclosporina - cÁpsula blanda - 50 mg - ciclosporina 50 mg - ciclosporina